PAMU
TVRD

Pictet Asset Management (UK)’s Tvardi Therapeutics TVRD Stock Holding History

Pictet Asset Management (UK)’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-21,553
Closed -$5.01M – 857
2016
Q2 		$5.01M Buy
21,553
+18,311
+565% +$3.99M 0.02% 579
2016
Q1 		$574K Hold
3,242
– – ﹤0.01% 784
2015
Q4 		$1.97M Buy
3,242
+1,148
+55% +$630K 0.01% 729
2015
Q3 		$1.08M Buy
+2,094
New +$1.4M ﹤0.01% 776

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Pictet Asset Management (UK)'s TVRD Position: Q3 2016 in Review

Pictet Asset Management (UK) sold out of Tvardi Therapeutics (TVRD) in Q3 2016, closing a stake of 21,553 shares — an estimated $5.01M sold.

Pictet Asset Management (UK) first reported a position in TVRD in Q3 2015 and held it in 4 quarters. The position peaked at $5.01M in Q2 2016. 81 funds tracked by Wall St. Rank hold TVRD as of Q3 2016.

  • Pictet Asset Management (UK) reported no remaining Tvardi Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Pictet Asset Management (UK) sold 21,553 Tvardi Therapeutics shares in Q3 2016, an estimated $5.01M.
  • Pictet Asset Management (UK) first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 4 quarters.
  • Pictet Asset Management (UK)'s Tvardi Therapeutics position peaked at $5.01M in Q2 2016.
  • 81 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2016.

Based on Pictet Asset Management (UK)'s 13F filing for Q3 2016, filed 14 Nov 2016.